STOCK TITAN

Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Editas Medicine, Inc. (Nasdaq: EDIT) announced that President and CEO Gilmore O’Neill will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. A live webcast of the presentation will be available on the company's website.
Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, 4:30 p.m. PT / 7:30 p.m. ET in San Francisco, CA.

A live webcast of the presentation will be available on the “Investors” section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available on the website for approximately 30 days following the presentation.

About Editas Medicine
As a clinical-stage genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.


President and CEO Gilmore O’Neill will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024.

The presentation will take place in San Francisco, CA.

A live webcast of the presentation will be available on the 'Investors' section of the Editas Medicine website at www.editasmedicine.com.

An archived replay will be available on the website for approximately 30 days following the presentation.
Editas Medicine Inc

NASDAQ:EDIT

EDIT Rankings

EDIT Latest News

EDIT Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
US
Cambridge

About EDIT

unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.